Guenther G. Steger

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Alison Stopeck, Allan Lipton, Jean-Jacques Body et al. · Journal of Clinical Oncology · 2010 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +17

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

Medicine, Oncology, Pharmacology +17

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger et al. · The Lancet Oncology · 2011 · 466 citations

Medicine, Oncology, Pharmacotherapy +17

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

David Cameron, Julia Brown, Rebecca Dent et al. · The Lancet Oncology · 2013 · 436 citations

Medicine, Oncology, Pharmacology +7